← All trials
NCT07166094
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2025
- Primary completion
- Nov 30, 2028
- Completion date
- Feb 28, 2029
- First posted
- Sep 10, 2025
- Last posted
- Nov 12, 2025
- Enrollment
- 544
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.